Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Equity Ratio (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Equity Ratio for 14 consecutive years, with 2.7 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio fell 138.81% year-over-year to 2.7, compared with a TTM value of 2.7 through Dec 2025, down 138.81%, and an annual FY2025 reading of 2.7, down 138.81% over the prior year.
  • Equity Ratio was 2.7 for Q4 2025 at Karyopharm Therapeutics, up from 2.8 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.05 in Q4 2022 and bottomed at 2.8 in Q3 2025.
  • Average Equity Ratio over 5 years is 0.84, with a median of 0.53 recorded in 2021.
  • The sharpest move saw Equity Ratio surged 82.18% in 2022, then tumbled 1118.19% in 2023.
  • Year by year, Equity Ratio stood at 0.26 in 2021, then soared by 82.18% to 0.05 in 2022, then crashed by 1118.19% to 0.57 in 2023, then plummeted by 99.71% to 1.13 in 2024, then plummeted by 138.81% to 2.7 in 2025.
  • Business Quant data shows Equity Ratio for KPTI at 2.7 in Q4 2025, 2.8 in Q3 2025, and 2.28 in Q2 2025.